NCT03971643View on ClinicalTrials.gov

Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

January 3, 2022

Study Completion Date

January 3, 2022

Conditions
Pyoderma Gangrenosum
Interventions
DRUG

vilobelimab

IV infusions of vilobelimab diluted in sodium chloride.

Trial Locations (10)

15213

InflaRx Site #09, Pittsburgh

17033

InflaRx Site #12, Hershey

33125

InflaRx Site #08, Miami

33613

InflaRx Site #03, Tampa

43210

InflaRx Site #05, Columbus

63110

InflaRx Site #10, St Louis

95816

InflaRx Site #07, Sacramento

Unknown

InflaRx Site #01, Richmond Hill

35-055

InflaRx Site #21, Rzeszów

50-566

InflaRx Site #20, Wroclaw

Sponsors

Lead Sponsor

InflaRx GmbH

Collaborators (1)

Innovaderm Research Inc.
All Listed Sponsors
collaborator

Innovaderm Research Inc.

OTHER

lead

InflaRx GmbH

INDUSTRY